Faculty Opinions recommendation of Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
Year: 2021
Type: peer-review
Abstract: Read the full review for this Faculty Opinions recommended article: Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
Author: David Teachey
Institution: Children's Hospital of Philadelphia
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: Amgen, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, Ariad Pharmaceuticals, Alexion Pharmaceuticals, Celgene, Karyopharm Therapeutics, Array BioPharma, Helsinn, Actinium Pharmaceuticals, Jazz Pharmaceuticals, TG Therapeutics, Astex Pharmaceuticals, Clovis Oncology, LAM Therapeutics, Sunesis, MEI Pharma, Agios Pharmaceuticals, Arog Pharmaceuticals, Mateon Therapeutics, Incyte, Celltrion, Argenx, Eisai, Astellas Pharma, Otsuka Pharmaceutical, Ono Pharmaceutical, Genentech, Helsinn Therapeutics, Kite Pharma, Pharmacyclics, Celator Pharmaceuticals, Daiichi Sankyo Europe
OpenAlex ID: W4210811689